Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes - Results from the PLATO Trial

Value in Health

Volumn 16, Issue 4, 2013, Pages 574-580

  Levin, Lars Åke ^a   Wallentin, Lars ^b   Bernfort, Lars ^a   Andersson, David ^a   Storey, Robert F ^c   Bergström, Gina ^d   Lamm, Carl Johan ^d   Janzon, Magnus ^a,e   Kaul, Padma ^f  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e Centre of Surgery and Oncology   (Sweden)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

acute coronary syndrome; clopidogrel; quality of life; ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUALITY OF LIFE; QUESTIONNAIRES; TICLOPIDINE; TIME FACTORS;

EID: 84879417494     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.01.013     Document Type: Article

References (23)

1. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
2. S. Husted, H. Emanuelsson, and S. Heptinstall Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
3. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856.
4. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
5. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
6. S. James, A. Akerblom, and C.P. Cannon Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 157 2009 599 605
7. P. Kind The EuroQoL Instrument: An Index of Health-Related Quality of Life 2nd ed 1996 Lippincott-Raven Philadelphia, PA
8. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72
9. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
10. Euroqol Group. Available from: http://www.euroqol.org/about-eq-5d/ valuation-of-eq-5d/eq-5d-3l-value-sets.html. [Accessed December 1, 2012.
11. M.T. Dyer, K.A. Goldsmith, and L.S. Sharples A review of health utilities using the EQ-5D in studies of cardiovascular disease Health Qual Life Outcomes 8 2010 13
12. L. Wei, and W.J. Shih Partial imputation approach to analysis of repeated measurements with dependent drop-outs Stat Med 20 2001 1197 1214
13. K. Unnebrink, and J. Windeler Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases Stat Med 20 2001 3931 3946
14. B. Schweikert, H. Hahmann, and R. Leidl Validation of the EuroQol questionnaire in cardiac rehabilitation Heart 92 2006 62 67
15. C. Hage, E. Mattsson, and A. Stahle Long-term effects of exercise training on physical activity level and quality of life in elderly coronary patients - a three- to six-year follow-up Physiother Res Int 8 2003 13 22
16. M. Kruse, S. Hochstrasser, and A.D. Zwisler Comprehensive cardiac rehabilitation: a cost assessment based on a randomized clinical trial Int J Technol Assess Health Care 22 2006 478 483
17. E.A. Lacey, R.J. Musgrave, and J.V. Freeman Psychological morbidity after myocardial infarction in an area of deprivation in the UK: evaluation of a self-help package Eur J Cardiovasc Nurs 3 2004 219 224
18. J. Kim, R.A. Henderson, and S.J. Pocock Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3) J Am Coll Cardiol 45 2005 221 228
19. S.V. Arnold, D.A. Morrow, and K. Wang Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial Circ Cardiovasc Qual Outcomes 1 2008 107 115
20. M. Janzon, L.A. Levin, and E. Swahn Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial Am Heart J 148 2004 114 121
21. Swedeheart Årsrapport (Annual report). Uppsala, Sweden: UCR, 2010.
22. J. Brazier, and R. Fitzpatrick Measures of health-related quality of life in an imperfect world: a comment on Dowie Health Econ 11 1 2002 17 19 discussion 21-2
23. G. Guyatt Commentary on Jack Dowie, "Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions" Health Econ 11 1 2002 9 12 discussion 21-2